Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + apatinib + irinotecan liposome in second-line HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2600135426Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- May 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of retlirafusp alfa, Rivoceranib and irinotecan liposome in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective response rate. Started May 2026; status: recruiting.
02
Drugs
retlirafusp alfaRivoceranibirinotecan liposome
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600135426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135426.